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A B S T R A C T
Vinpocetine (ethyl apovincaminate), a synthetic derivative of the Vinca minor alkaloid vincamine, is
widely used for the treatment of cerebrovascular-related diseases. One of the proposed mechanisms
underlying its action is to protect against the cytotoxic effects of glutamate overexposure. Glutamate
excitotoxicity leads to the disregulation of mitochondrial function and neuronal metabolism. As
Vinpocetine has a binding afﬁnity to the peripheral-type benzodiazepine receptor (PBR) involved in the
mitochondrial transition pore complex, we investigatedwhether neuroprotection can be at least partially
due to Vinpocetine’s effects on PBRs.
Neuroprotective effects of PK11195 and Ro5-4864, two drugs with selective and high afﬁnity to PBR,
were compared to Vinpocetine in glutamate excitotoxicity assays on primary cortical neuronal cultures.
Vinpocetine exerted a neuroprotective action in a 1–50 mMconcentration rangewhile PK11195 and Ro5-
4864 were only slightly neuroprotective, especially in high (>25 mM) concentrations. Combined
pretreatment of neuronal cultures with Vinpocetine and PK11195 or Ro5-4864 showed increased
neuroprotection in a dose-dependent manner, indicating that the different drugs may have different
targets. To test this hypothesis, mitochondrial membrane potential (MMP) of cultured neurons was
measured by ﬂow cytometry. 25 mM Vinpocetine reduced the decrease of mitochondrial inner
membrane potential induced by glutamate exposure, but Ro5-4864 in itself was found to bemore potent
to block glutamate-evoked changes in MMP. Combination of Ro5-4864 and Vinpocetine treatment was
found to be even more effective.
In summary, the present results indicate that the neuroprotective action of vinpocetine in culture can
not be explained by its effect on neuronal PBRs alone and that additional drug targets are involved.
 2008 Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Neurochemistry International
journa l homepage: www.e lsevier .com/ locate /neuint1. Introduction
A longer than transient deﬁcit in focal cerebral perfusion can
result in ischemic stroke, which is one of the main causes of
mortality and disability in Western societies. A consequence of
ischemia is cerebral damage caused mostly by glutamate-* Corresponding author at: Department of Physiology and Neurobiology, Eo¨tvo¨s
Lora´nd University, Pa´zma´ny P. stny. 1/C, H-1117 Budapest, Hungary.
Tel.: +36 1 381 2181; fax: +36 1 381 2182.
E-mail address: tarnokk@freemail.hu (K. Ta´rnok).
Abbreviations: MMP, mitochondrial membrane potential; MPTP, mitochondrial
permeability transition pore; PBR, peripheral-type benzodiazepine receptor/
translocator protein (18 kDa); VDSC, voltage-gated sodium channel; [Ca2+]i,
intracellular Ca2+ level.
0197-0186/$ – see front matter  2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2008.08.003mediated excitotoxicity (for review, see Won et al., 2002).
Neuronal release of glutamate following cerebral ischemia causes
an excess and sustained activation of glutamate receptors. A
massive Na+ and Ca2+ inﬂux through activated glutamate
receptors results in increased intracellular Ca2+ concentration
([Ca2+]i) and, as a consequence, in cell swelling. If ATP-dependent
Ca2+ efﬂux and/or Ca2+ uptake of mitochondria, endoplasmatic
reticulum and coremembrane are impaired, accumulation of Ca2+
in the cytoplasm leads to cytotoxicity. Additionally, high [Ca2+]i
activates Ca2+-dependent enzymes (proteases, kinases, lipases,
endonucleases and other catabolic enzymes) and leads to the
formation of NO or reactive oxidative species resulting in
oxidative stress (Kristian and Siesjo, 1998). These processes
eventually cause cell death either due to impairment of
membrane structure, cytoskeleton and cellular metabolism or
K. Ta´rnok et al. / Neurochemistry International 53 (2008) 289–295290indirectly, via the initiation of apoptotic pathways (Won et al.,
2002; Hazell, 2007).
The onset of deleterious cellular events upon increased [Ca2+]i
depends greatly on mitochondrial activity, as the transport of Ca2+
from the cytoplasm into the mitochondrial matrix is driven by
mitochondrial membrane potential (MMP) (Duchen, 2000; Nicholls
and Ward, 2000). MMP is generated in the inner mitochondrial
membranedue toaprotongradientprovokedby theoperationof the
respiratory chain. In the depolarised mitochondria, oxidative
phosphorylation is hampered and diminished ATP production
enhances the cytotoxic effects of Ca2+ by increasing [Ca2+]i (Nicholls,
2004). When mitochondrial Ca2+ accumulation persists over longer
periods of time, overloaded mitochondria produce oxidative
species (Giulivi et al., 2006). As a consequence, mitochondrial
permeability transition pore complex (MPTP) is opened, leading to
the dissipation ofMMP and the streamof accumulated Ca2+ into the
cytoplasm (Green and Reed, 1998; Nicholls and Ward, 2000).
Opened MPTP can also lead to the release of several other cytotoxic
compounds (e.g. apoptosis-inducing factor and cytochrome c),
which further enhances apoptotic processes (Kroemer and Reed,
2000; Luetjens et al., 2000). Therefore, attempts to preserve
neuronal mitochondrial functions under excitotoxic conditions
are considered as important strategic approaches (Norenberg and
Rao, 2007; Won et al., 2002).
Peripheral-type benzodiazepine receptor (PBR) or as recently
renamed, translocator protein 18 kDa (TSPO), is an outer mito-
chondrial transmembrane protein. Recently, PBR has been
regarded as one of the feasible targets to preserve the functions
of mitochondria (Casellas et al., 2002; Castedo et al., 2002;
Veenman and Gavish, 2006). Namely, PBR is known to interact
with several residentmitochondrial proteins, in particularwith the
voltage-dependent anion channel (VDAC) in the outer andwith the
adenine nucleotide translocase (ANT) in the inner mitochondrial
membrane. Importantly, these proteins form the backbone of
MPTP (McEnery et al., 1992; Gavish et al., 1999) and take part in the
regulation of MPTP and apoptosis (Chelli et al., 2001, 2004;
Azarashvili et al., 2007; Li et al., 2007). Moreover, PBR ligands can
modulate oxidative stress (Fennell et al., 2001; Jayakumar et al.,
2002) and PBR expression is increased in response to nervous
tissue injury (Lacor et al., 1996, 1999;Weissman and Raveh, 2003).
PBR is also thought to play a role in steroid biosynthesis and
cholesterol transport, as well as in the control of mitochondrial
energy production (for reviews, see Casellas et al., 2002;
Papadopoulos et al., 2006a,b; Gavish et al., 1999).
Vinpocetine (14-ethoxycarbonyl-(3a,16a-ethyl)-14,15-eburna-
mine; Cavinton), a synthetic derivative of the lesser periwinkle
plant (Vinca minor) alkaloid vincamine, is widely used as a
neuroprotective agent for the prevention and treatment of central
nervous system disorders of cerebrovascular origin. Its beneﬁcial
clinical effects are based on a wide range of action mechanisms
including antioxidant, vasodilating and neuroprotective effects,
however, the precise nature of the underlying mechanistic
processes is not yet clear (Bonoczk et al., 2000; Vas and Gulyas,
2005). Recent studies indicated that Vinpocetine has a relatively
high potency towards PBR, raising the possibility that the
pharmacological action of Vinpocetine may involve the regulation
of PBR function (Gulyas et al., 2005).
In the present study, we examined the neuroprotective effects
of Vinpocetine in glutamate excitotoxicity assays on embryonic
cortical neurons by analysing changes inmitochondrial membrane
potential and cell viability. Since Vinpocetine has a binding afﬁnity
to PBR, neuroprotective effects of Vinpocetine were also compared
to the effects of isoquinoline carboxamide (PK11195) and 40-
chlorodiazepam (Ro5-4864), two drugs with selective and high
afﬁnity to PBR (Le Fur et al., 1983).2. Materials and methods
2.1. Primary neuronal cultures
Primary cortical neurons were prepared from 15- to 16-day-oldmouse embryos.
Under aseptical conditions, embryonic brains were prepared and transferred to
DMEM supplemented with Amphotericine B (2.5 mg/ml) and 1% PenStrep (all from
Sigma, NL). Cortices were isolated, cleaned from meninges and were incubated in
0.05% trypsin solution (Gibco, Invitrogen, NL) for 15 min at 37 8C. After a brief
centrifugation, cells were triturated in NeuroBasal media supplemented with B27
(Gibco, Invitrogen, NL), 0.5 mM Glutamine, 1% PenStrep, 2.5 mg/ml Amphotericine
B and ﬁltered through a sterile polyester mesh with 42 mm pore size (EmTek Ltd.,
Hungary). Cell number was determined by trypan blue exclusion, and cells were
seeded onto poly-D-lysine (PDL, Sigma, NL) coated Petri dishes or coverslips at
105 cells/ cm2 density in NeuroBasal media supplemented with B27, 0.5 mM
Glutamine, 1% PenStrep, 2.5 mg/ml Amphotericine B. Cells were cultivated at 37 8C
in 5% CO2/95% air atmosphere. To prevent the division of non-neuronal cells, 2-day-
old cultures were treated with 10mM cytosine-arabinofuranoside (CAR, Sigma, NL)
for 1 day.
2.2. Measurement of intracellular free calcium ([Ca2+]i) levels in single cells
Cortical neurons isolated from 15- to 16-day-old embryos were grown on PDL-
coated glass coverslips in 35 mm dishes. 6 days after plating, cultures were washed
with physiological solution containing 140 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl2,
10 mM Hepes, 10 mM D-glucose, 10mM glycine (pH 7.2, 300 mOsm) and loaded
with 5mM Fura-2AM dye (Molecular Probes, Invitrogen, Hungary) for 30 min at RT
in the above buffer solution. At the end of the incubation, excess Fura-2AM was
removed and cultures were further incubated for 30 min to completely hydrolyse
the Fura-ester. [Ca2+]i was determined under constant perfusion at RT (22 8C), using
an inverted Olympus IX81 microscope with a 40 objective, MT-20 external
illumination and the CellR software (Olympus, Hungary). Optical measurements
were obtained by alternate excitation at 340 and 380 nm, with 350 ms frame rates.
Fluorescent signals were detected by a cooled C9100-13 EM-CCD Hamamatsu
camera (Hamamatsu Photonics, Herrsching am Ammersee, Germany), using a 510/
30 nm bandpass ﬁlter. 25 mM glutamate (Sigma, Hungary) and 25 mM Vinpocetine
(Richter Ltd., Hungary) were added via the perfusion system at 1 ml/min ﬂow rate.
25 mM Vinpocetine was perfused for 30 min before the glutamate treatment and
was also present during the 30 min long glutamate administration. Data were
evaluated by the CellR software provided by Olympus (Hungary). In order to
compare [Ca2+]i responses of cells in different measurements, calculated DF/F
values (changes in the ratio) were normalized to the highest value of the initial
[Ca2+]i response (100%). NormalizedDF/F values were compared by Student’s t-test
(signiﬁcance level was set to p < 0.05).
2.3. Drug preparation
Vinpocetine (Richter Ltd., Hungary), PK11195 (1-(2-chlorophenyl)-N-methyl-N-
(1-methylpropyl)-3-isoquinolinecarboxamide, Sigma, NL) and Ro5-4864 (7-chloro-
5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one, Sigma,
NL) were stored at 4 8C in 10 mM stock concentration in cc. DMSO (Sigma, NL).
FCCP (Mesoxalonitrile 4-triﬂuoromethoxyphenylhydrazone, Sigma, Hungary) was
dissolved in 95% ethanol to create 10 mM stock solution.
2.4. Glutamate excitotoxicity assays and viability tests
Glutamate excitotoxicity assays were performed on embryonic cortical neurons
6 days after plating. Conditioned media of the cultures were collected before the
drug treatment. Cells were treated with different drugs at the indicated
concentrations in fresh media for 30 min, followed by a 1 h long treatment with
33 mM glutamate. Drugs were present during the glutamate administration, as
well. After the glutamate treatment, conditionedmediawere given back to the cells.
Viability of the cultures was measured 24 h later by MTT assay, according to
Mosmann (1983). Brieﬂy, cells grown in 96-well plates were treated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) in a ﬁnal
concentration of 250mg/ml. After 2 h incubation, cells and formazan crystals were
dissolved in acidic (0.08 M HCl) isopropanol (Merck). Optical density was
determined at a measuring wavelength of 570 nm against 630 nm as reference
with Biorad ELISA reader. Assays were carried out on eight parallel wells. To
compare the data obtained from different measurements, average viability values
were expressed as a percentage ofmaximum cell death observed in cultures treated
with glutamate only. Data are shown as averages and standard deviations and were
compared by Student’s t-test (p < 0.05).
2.5. Detection of mitochondrial membrane depolarisation
Analysis of mitochondrial membrane potential of primary neurons was
performed by Becton-Dickinson FACSCalibur ﬂow cytometer equipped with
argon-ion laser according to the methods described by Lecoeur et al. (2004) with
Fig. 1. Intracellular Ca2+ changes in embryonic cortical neurons during 25mM
glutamate treatment in the presence or in the absence of 25mM Vinpocetine. (a)
Average relative DF/F values of glutamate (open circles; n = 55) or glutamate and
25mM Vinpocetine (black circles; n = 31) treated neurons. DF/F values were
normalized to the highest value of the initial [Ca2+]i response (100%). Arrow
indicates the start of 25mM glutamate administration, which was continued for
30 min. Data are presented as average and standard deviation; *p < 0.05. (b) Peak
DF/F values of the initial Ca2+ answers of neurons treated by glutamate (white bar)
or glutamate and Vinpocetine (black bar). (c) RelativeDF/F values determined 9 min
after the onset of glutamate or glutamate and Vinpocetine treatment. Data are
presented as average and standard deviation and are related to the level of the
initial [Ca2+]i rises (100%); *p < 0.001.
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of 5  105 cells/well. 6 days after plating, neurons were treated with glutamate and
drugs according to the experiments. During the last 20 min of glutamate treatment,
cultures were stained by 40 nM 3,30-dihexyloxacarbocyanine iodide (DiOC6(3),
Molecular Probes/Invitrogen), a MMP-sensitive dye, at 37 8C in dark. At the end of
the treatment, cells were washed by phosphate buffered saline (PBS) and incubated
with 250ml/well of 37 8C 0.05% trypsin–EDTA solution (Gibco, Invitrogen) for 5 min
at 37 8C. Cells were carefully harvested and suspended in 500 ml B27 free
NeuroBasal media (Gibco, Invitrogen) by gentle ﬂushes. To label the dying cells, cell
suspensions were stained by 10mg/ml propidium iodide (PI) (Sigma). Flow
cytometry measurements were carried out immediately after trypsinisation.
Emission of DiOC6(3) was detected in the FL1 channel (530/30 nm bandpass
ﬁlter) and impaired cells were identiﬁed by their decreased MMP (DiOC6(3)
LOW
cells). Late apoptotic/necrotic cells were identiﬁed by increased propidium iodide
uptake measured in the FL3 channel (670 nm longpass ﬁlter). We also used the
forward side scatter (FSC) intensity, which roughly equals to the particle’s size and
can also be used to distinguish between cellular debris and living cells (see Fig. 4a).
During the analyses, the FSCHIGH and PILOW population was regarded as healthy
cells. Data acquisition and analysis were performed using CellQuest Pro software.
20,000 cells were sorted in each measurement and only the FSCHIGH/PILOW cell
population (55–60% of analysed cells) were used for detailed analyses. In order to
compare the effects of the applied drugs, changes in the ratio of DiOC6(3)
LOW cells
upon different treatments were normalized to the change of DiOC6(3)
LOW cells
population caused by 150mM glutamate treatment alone (100%). Data are
presented as averages and standard deviation from 3-3 different measurements
of 10 independent cultures.
3. Results
3.1. Vinpocetine can reduce [Ca2+]i elevations evoked by
glutamate treatment
Former studies indicated that under excitotoxic conditions
caused by opening of voltage-dependent sodium channels, Vinpo-
cetine exerted neuroprotective effects at least partly by decreasing
Ca2+ inﬂux and intracellular free Ca2+ level, as well (Tretter and
Adam-Vizi, 1998; Sitges and Nekrassov, 1999; Zelles et al., 2001;
Sitges et al., 2006). To test whether Vinpocetine can activate similar
mechanisms during glutamate-induced excitotoxicity, ratiometric
Fura-2 Ca2+ imaging was performed in embryonal cortical neuronal
cultures 6 days after plating (Fig. 1). Changes in [Ca2+]i were
measured upon exposure to 25mM glutamate, either without or in
the presence of 25mMVinpocetine (Fig. 1a). In case of Vinpocetine-
treatedcultures,Vinpocetinewasperfused for30 minalreadybefore
the onset of glutamate treatment.
Regardless to the presence of Vinpocetine, initial [Ca2+]i rise
was similar in the neurons upon glutamate exposure (Fig. 1b).
Within 10 min, however, elevated [Ca2+]i level was reduced
signiﬁcantly (Fig. 1c), which was maintained throughout the
additional 20 min of the investigations, as well (81.7  10.8 or
109.2  9.1% of the initial [Ca2+]i peak in cultures with or without
Vinpocetine treatment, respectively. p < 0.001).
3.2. Neuroprotective effect of Vinpocetine and peripheral
benzodiazepine receptor-binding compounds after glutamate
excitotoxicity
According to recent studies, Vinpocetine has binding afﬁnity to
peripheral benzodiazepine receptor (Gulyas et al., 2005; Vas et al.,
2008). Vinpocetine-mediated effects on embryonal cortical neu-
rons were measured in toxicity tests and compared to the action of
isoquinoline carboxamide (PK11195) and 40-chlorodiazepam
(Ro5-4864), which have selective and high binding afﬁnity to
PBRs (Gavish et al., 1999; Casellas et al., 2002). Based on the
entropy-driven and enthalpy-driven nature of ligand–receptor
interactions, PK11195 and Ro5-4864 have been classiﬁed as an
antagonist and agonist, respectively (Le Fur et al., 1983).
Neuroprotective action of 1.5 h treatment with Vinpocetine,
PK11195 or Ro5-4864 was determined by MTT assay, 24 h afterthe onset of drug administration. According to our data, neither
of the compounds had any toxic effects in the 10 nM to 50 mM
concentration range (data not shown). In glutamate excitotoxi-
city assays initiated by 1 h treatment with 33 mM glutamate,
1 mM Vinpocetine already exerted slight neuroprotection, which
was increased further in a dose-dependent manner (Fig. 2).
50 mM Vinpocetine had a strong neuroprotective effect and
decreased cell death by 74.9  7.6%. On the other hand, Ro5-4864
and PK11195 exerted signiﬁcantly lower neuroprotection and were
effective only in high (>25 mM) concentration. In case of 50 mM
treatment, Ro5-4864 had a signiﬁcantly increased neuroprotective
action compared to PK11195 (76.9  5 and 65.5  8%, respectively;
p < 0.001).
The level of neuroprotectionupon combiningVinpocetinewith
either PK11195 or Ro5-4864 was also investigated (see Fig. 3a for
the experimental schedule). At the beginning of the experiments,
PK11195 or Ro5-4864 was added to the cultures in various
concentrations for 30 min followed by an additional 10 mM
Vinpocetine treatment. After a further 30 min of incubation,
33 mMglutamate treatmentwas applied for 1 h in the presence of
all previously added compounds. 24 h upon the removal of
glutamate and the various drugs from the cultures, cell viability
was checked by MTT assay. Both PK11195 (Fig. 3b) and Ro5-4864
(Fig. 3c) increased neuroprotection exerted by Vinpocetine alone
(indicated by dashed lines in Fig. 3b and c) in a dose-dependent
manner, but signiﬁcant alterations were found only when
PK11195 and Ro5-4864 were present at a concentration higher
than 10 mM. These ﬁndings already indicate that the mode of
action exerted by Vinpocetine and the PBR-binding drugs may be
different.
Fig. 2. Dose-dependent neuroprotective effects of 10–50mM Vinpocetine (ﬁlled
diamond), Ro5-4864 (open triangle) or PK11195 (open box) on cortical neurons.
Control cultures were treated with DMSO only (ﬁlled box). In all cases, cells were
pretreated with the corresponding drugs for 30 min before the onset of the
glutamate treatment (1 h, 33mM). Drugs were present also during glutamate
administration. Cellular viability was measured by MTT assay 24 h after the
glutamate treatment and data were normalized to the level of maximum cell death
observed in cultures treated onlywith glutamate. Data are presented as average and
standard deviation. *p < 0.01, comparing Vinpocetine-treated values to solvent-
only treated values; yp < 0.01, comparing Ro5-4864 and PK11195 treated values to
solvent-only treated values; zp < 0.01, comparing Ro5-4864 and PK11195 treated
values to each other.
Fig. 3. Neuroprotective effects of Vinpocetine combined with PBR-selective drugs.
(a) Schematic representation of the experimental design. Neurons were treated
with PK11195 (b) or Ro5-4864 (c) in various concentrations for 30 min, then 10 mM
Vinpocetine was also added to the cultures. Excitotoxicity was induced by 1 h of
glutamate treatment (33mM) and cellular viability was measured 24 h after the
glutamate treatment. Data were normalized to the level of maximum cell death
observed in control, glutamate-only treated cultures (100%). On (b) and (c), dashed
line indicates the average neuroprotection evoked by 10 mM Vinpocetine alone.
Data are presented as averages and standard deviations; *p < 0.05, in comparison to
the Vinpocetine-only treated values.
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depolarisation caused by excitotoxic conditions
PBRs are suggested as members or modulators of the MPTP
(McEnery et al., 1992; Casellas et al., 2002; Papadopoulos et al.,
2006a), whose opening can directly inﬂuence MMP (Kroemer and
Reed, 2000). According to previous publications, Vinpocetine has a
binding afﬁnity towards PBRs (Gulyas et al., 2005; Vas et al., 2008),
raising the possibility that Vinpocetine can affect mitochondrial
membrane potential changes via interacting with PBRs. In order to
test this hypothesis, we used an MMP-sensitive dye, 3,30-
dihexyloxacarbocyanine iodide in ﬂow cytometry to follow
changes in neuronal MMP upon glutamate treatment.
As deregulation of MMP upon excitotoxic stimuli precedes
apoptotic processes and cell death (Nicholls and Ward, 2000;
Nicholls, 2004), ﬂow cytometrywas carried out directly after the 1 h
long treatment with glutamate. In this case, treatment with 25mM
Vinpocetine, Ro5-4864 or PK11195 was started 30 min before the
glutamate exposure and continued during the glutamate adminis-
tration period. After the incubation steps, primary cortical neurons
were gently harvested by trypsinisation and cell suspensions were
subjected to ﬂow cytometry. Membrane integrity of the harvested
neuronswas checked bypropidium iodide staining, cell volumewas
characterised by forward side scatter value and only healthy cells
were used for evaluations (PILOWand FSCHIGH cells; Fig. 4a). Addition
of 10mM FCCP, a known mitochondrial protonophor (Azarashvili
et al., 2007), strongly shifted DiOC6(3) ﬂuorescence towards lower
values, while 25 mM KCl treatment, known to depolarise plasma
membrane, did not have lower MMP (Fig. 4b). Initial titration
experiments also showed that treatment with 150mM glutamate
signiﬁcantly increased the ratio of cells possessing low MMP
(DiOC6(3)
LOW population) (Fig. 4c). These data unequivocally show
that our method was suitable to compare the effects of Vinpocetine
to effects of the PBR ligands upon glutamate-inducedMMP changes.When Vinpocetine, Ro5-4864 or PK11195 (all in 25 mM) were
present during glutamate treatment, the amount of cells with
decreased MMP was signiﬁcantly decreased compared to
glutamate-only treated cultures (Fig. 4d). On the other hand,
Ro5-4864 was signiﬁcantly more effective than Vinpocetine or
PK11195 treatment alone, while PK11195 exerted similar
protective effects to Vinpocetine (Table 1). Moreover, the
combination of Vinpocetine with Ro5-4864 or PK11195 further
decreased the proportion of DiOC6(3)
LOW population indicating a
stronger neuroprotection. The changes were signiﬁcant in both
cases (Table 1). According to these results, strongest neuropro-
tection was obtained with the combined use of Vinpocetine
together with Ro5-4864.
4. Discussion
Under in vivo ischemic conditions, primary neuronal cell death
appears rapidly in the ischemic core region. As a result of the
activation of multiple death pathways, this initial process is
Fig. 4. Effects of Vinpocetine, Ro5-4864 and PK11195 on mitochondrial membrane potential (MMP) during glutamate treatment. MMP of dissociated cortical neurons was
measured by ﬂow cytometry using DiOC6(3), a MMP-sensitive dye. (a) For data evaluation, only the healthy (FSC
HIGH and PILOW) cells were considered (see cells plotted in the
area delineated by the dashed line). (b) 10mM FCCP strongly shifted DiOC6(3) ﬂuorescence towards lower MMP values, while 25 mM KCl treatment slightly enhanced
DiOC6(3) labelling. (c) 150 mM glutamate (black line) increased the amount of cells with low DiOC6(3) ﬂuorescence. (d) Relative changes in the proportion of DiOC6(3)
LOW
cells after glutamate treatment and in combination with Vinpocetine, Ro5-4864 or PK11195 treatment. Data were normalized to the change of DiOC6(3)
LOW cells population
caused by 150mM glutamate treatment alone (100%). The ratio of neurons possessing lowMMP in glutamate and various drug-treated cultures was decreased signiﬁcantly
compared to the effects of glutamate treatment alone (not indicated; p < 0.001). Ro5-4864 in itself exerted higher neuroprotection than Vinpocetine alone (*p < 0.01). The
combination of Vinpocetine with Ro5-4864 or PK11195 increased further the neuroprotective effect (yp < 0.05, in comparison to the Vinpocetine-only treated values, for
more details, see Table 1).
K. Ta´rnok et al. / Neurochemistry International 53 (2008) 289–295 293followed by a secondary delayed cell death in the penumbra area
(seeWon et al., 2002 for a review). A key element of the secondary
cell loss is the increased activity of excitatory amino acid regulated
receptors, which elevates [Ca2+]i above the physiological levels and
leads to disturbed functions and eventually cell death (De Keyser
et al., 1999; Nicholls, 2004; Hazell, 2007). Former clinical and
experimental studies in vivo and in vitro have shown that
Vinpocetine, developed by Richter Ltd., is able to protect the
neurons under ischemic condition by a variety of actions (BonoczkTable 1
Effects of Vinpocetine, Ro5-4864 and PK11195 on mitochondrial membrane potential
Treatment Relative changes in the
proportion of DiOCLOW6 cells (%)
p
V
Vinpocetine 67.43  7.43*
Ro5-4864 53.74  5.41* 0
Ro5-4864 and Vinpocetine 44.14  3.47* 0
PK11195 64.99  11.90* 0
PK11195 and Vinpocetine 48.56  7.45* 0
Data were normalized to the change of DiOC6(3)
LOW cells population caused by 150 m
compared to cultures treated with glutamate only. p values less than 0.05 were regardet al., 2000; Vas and Gulyas, 2005). Vinpocetine can block
phosphodiesterase I, which can be important for improvement
of cerebral circulation (Pelligrino and Wang, 1998) and can act as
an antioxidant (Vas and Gulyas, 2005). Vinpocetine also blocks
voltage-gated sodium channels (VDSCs) in therapeutically relevant
concentrations (<50 mM), decreases the Ca2+ inﬂux evoked by
VDSC stimulation and can also attenuate Ca2+-dependent destruc-
tive processes (Lakics et al., 1995; Tretter and Adam-Vizi, 1998;
Sitges and Nekrassov, 1999; Zelles et al., 2001; Sitges et al., 2006).(MMP) during glutamate treatment
values compared to
inpocetine-only treated cultures






M glutamate treatment alone (100%). * indicates signiﬁcant changes (p < 0.0001)
ed as signiﬁcant changes.
K. Ta´rnok et al. / Neurochemistry International 53 (2008) 289–295294The present study shows that therapeutically relevant con-
centration (<50 mM) of Vinpocetine helps to recover increased
[Ca2+]i level evoked by chronic glutamate administration in
primary cortical neuronal cultures. This result is consistent with
former ﬁndings on veratridine-induced [Ca2+]i changes (Tretter
and Adam-Vizi, 1998; Zelles et al., 2001; Sitges et al., 2006).
Importantly, Vinpocetine did not inﬂuence the amplitude of the
initial glutamate-evoked [Ca2+]i rise indicating that Vinpocetine
acts at least partially by inﬂuencing mechanisms controlling
elevated [Ca2+]i levels. Recent positron emission tomography (PET)
studies using radiolabeled PBR ligands and Vinpocetine suggested
that mitochondrial peripheral-type benzodiazepine receptors can
be therapeutically relevant targets of Vinpocetine (Gulyas et al.,
2005; Vas and Gulyas, 2005). As mitochondria play an important
role in Ca2+ homeostasis, neuroprotective effects of Vinpocetine
can be executed through interfering with PBRs and consequently,
via modulating mitochondrial function.
In the last decade, the involvement of PBRs in neurological
conditions was extensively investigated using PBR ligands or PBR
overexpressing cells (Gavish et al., 1999; Fischer et al., 2001;
Casellas et al., 2002; Papadopoulos et al., 2006b). Accordingly, PBRs
were found to be preferentially localised in the outer membrane of
mitochondria (O’Beirne and Williams, 1988; Hirsch et al., 1989).
Several studies indicated that PBR-mediated changes in mitochon-
drial function can play a key role during apoptotic events
(Tanimoto et al., 1999; Casellas et al., 2002; Chelli et al., 2004;
Azarashvili et al., 2005; Li et al., 2007). Recently, PBRs have been
shown to directly regulate MPTP opening (Chelli et al., 2001;
Azarashvili et al., 2007), which is one of the ﬁrst steps in apoptotic
cascades.
To investigate the role of PBRs in glutamate excitotoxicity, we
compared the neuroprotective effect of Vinpocetine with the
beneﬁcial action of the speciﬁc synthetic PBR ligands, isoquinoline
carboxamide (PK11195) and 40-chlorodiazepam (Ro5-4864). In our
in vitro glutamate excitotoxicity assays, PK11195 or Ro5-4864
exerted signiﬁcantly less neuroprotection and needed higher
concentration than that observed in Vinpocetine-treated cultures.
Combination of the different drug treatments increased neuro-
protection, indicating partly different mode of action between
Vinpocetine and PK11195 or Ro5-4864. These results suggest that
the underlying mechanisms and/or the binding sites of Vinpoce-
tine versus PK11195 or Ro-5-4864 may be at least partially
different, which was also suggested in PET studies, as well (Vas
et al., 2008).
The neuroprotective role of PK11195 and Ro5-4864 is a matter
of debate and both pro- and anti-apoptotic effects in neuronal
primary cultures have been reported (Jayakumar et al., 2002;
Parker et al., 2002; Jorda et al., 2005; Mills et al., 2005). In our
hands, Ro5-4864 proved to be more potent than PK11195 to
protect the cells from glutamate-evoked excitotoxicity both in
viability tests and ﬂow cytometry experiments. This is in line with
former observation on hippocampal neurons during kainic acid-
induced excitotoxicity (Veiga et al., 2005) or in sensory neuron
regeneration (Mills et al., 2005). The different action of these drugs
may rely on their different binding site(s) or on the different
modulation of their binding sites by other members of the PBR
complex, e.g. by VDAC (Joseph-Liauzun et al., 1997; Lacapere et al.,
2001; Garnier et al., 1994).
Interestingly, Ro5-4864 proved to be more effective in
preserving normal MMP than Vinpocetine alone. Furthermore,
the effects of PBR drugs were potentiated by Vinpocetine. These
ﬁndings suggest that regulation of [Ca2+]i levels and MMP can take
place in partially different ways and allow the conclusions that
PK11195 and Ro5-4864 exert amore direct action onmitochondria
than Vinpocetine.Taken together, our results suggest that during in vitro
glutamate excitotoxicity, neuronal PBRs are not likely the primary
targets for the neuroprotective action exerted by Vinpocetine. The
outcome of combined treatmentwith Vinpocetine and speciﬁc PBR
associated drugs in excitotoxicity experiments and mitochondrial
membrane potential preservation indicates at least a partly
different mode of action. It is a feasible explanation that the
observed restoration of MMP and the reduction of excitotoxic cell
death is a consequence of Vinpocetine’s attenuating effect on
elevated intracellular Ca2+ levels.
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